Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Triptodur prior auth & coverage | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0308

    Triptodur® (triptorelin) (Intramuscular) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0308 alerts

    Get alerted when Policy IC-0308 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Viva Health prior authorization, dosing, indications, renewal, billing codes, and clinical criteria for Triptodur® (triptorelin) intramuscular 6-month formulation for members, including pediatric central precocious puberty and gender dysphoria indications.

    Policy Summary
    PayerViva Health
    PolicyTriptodur® (triptorelin) (Intramuscular) — Coverage Criteria
    Policy CodePolicy IC-0308
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial PA valid for 12 months and renewable every 12 months) and include required clinical documentation to support the indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J3316HCPCS billing code
    NDC 24338-0150-xxProduct NDC
    22.5 mg q24 weeksDosing
    6Max billable units /168d

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Initial PA duration

    Coverage Criteria

    Initial Therapy — Central Precocious Puberty (CPP)

    Covered when ALL of the following are met

    CPP initial criteria: Member is between the ages of 2 and less than 13 years; AND will not be used in combination with growth hormone; AND onset of secondary sexual characteristics earlier than age 8 for females and 9 for males associated with pubertal pituitary gonadotropin activation; AND diagnosis is confirmed by pubertal gonadal sex steroid levels and a pubertal luteinizing hormone (LH) response to stimulation by native GnRH; AND bone age advanced greater than 2 standard deviations (SD) beyond chronological age; AND tumor has been ruled out by lab tests and imaging (brain imaging, pelvic/testicular/adrenal ultrasound) and human chorionic gonadotropin (hCG) levels to exclude chorionic gonadotropin–secreting tumor

    Initial Therapy — Gender Dysphoria

    Covered when ALL of the following are met

    Gender dysphoria initial criteria: Member has experienced puberty development to at least Tanner stage 2 (applies only to members <18 years); AND member has a diagnosis of gender dysphoria confirmed by a qualified mental health professional (MHP) or DSM-5-TR criteria; AND a qualified MHP has confirmed a long‑lasting and intense pattern of gender nonconformity or dysphoria, worsening with onset of puberty, that coexisting psychological/medical/social problems that could interfere with treatment have been addressed, and the member has sufficient mental capacity to give informed consent to this reversible treatment; AND member has been informed of effects/side effects (including potential loss of fertility) and options to preserve fertility and has given informed consent with parental/guardian involvement when applicable; AND for adolescents, a pediatric endocrinologist or clinician experienced in pubertal assessment has confirmed agreement in the indication for treatment and absence of medical contraindications

    Continuation / Renewal Criteria

    Renewal authorization provided when ALL of the following are met

    Universal renewal: Member continues to meet the universal criteria and indication-specific relevant criteria identified in section III; AND absence of unacceptable toxicity from the drug (examples include psychiatric events, convulsions, severe cutaneous adverse reactions, signs/symptoms of pseudotumor cerebri/idiopathic intracranial hypertension); AND for CPP: member is <13 years and shows disease response evidenced by lack of progression or stabilization of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improved final height prediction; AND for gender dysphoria: member has shown a beneficial response evidenced by routine monitoring of pubertal development and applicable laboratory parameters

    For Central Precocious Puberty (CPP) initial authorization, Triptodur must not be used in combination with growth hormone. This exclusion is a required element of the CPP initial-therapy criteria and claims that include concurrent growth hormone for CPP initial approval do not meet the coverage criteria.

    The policy lists ICD-10 diagnosis codes in Appendix 1 for covered indications. Note that F64.9 (Gender identity disorder, unspecified) is identified in the appendix as Discontinued effective 10/1/26 and therefore is not retained as a continuing code after that date.

    Coding and Billing

    Covered HCPCS CodesHCPCSCovered
    J3316Injection, triptorelin, extended-release, 3.75 mg; 1 billable unit = 3.75 mg
    Product NDCNDC
    24338-0150-xxTriptodur 22.5 mg single-use kit NDC
    Covered ICD-10 Diagnosis CodesICD-10Covered
    E30.1Precocious puberty
    E30.8Other disorders of puberty
    F64.0Transsexualism
    F64.1Dual role transvestism
    F64.2Gender identity disorder of childhood
    F64.8Other gender identity disorders
    F64.9Gender identity disorder, unspecified (Discontinued effective 10/1/26)
    F64.AGender identity disorder, in remission (Effective 10/1/26)
    Maximum billable units per dosing interval
    Maximum billable units6 billable units (equivalent to 22.5 mg) per 168 days
    HCPCS unit equivalence1 billable unit = 3.75 mg (J3316) — 6 units = 22.5 mg
    Time intervalPer 168 days

    Provider Actions and Prior Authorization

    Prior Authorization

    Obtain prior authorization (initial 12 months)

    Prior authorization is required for Triptodur; initial PA validity will be provided for 12 months (365 days) and may be renewed every 12 months (365 days) thereafter.

    Prior Authorization

    PA may be required per NQTL factors

    Prior authorization may be required based on the indication and cost considerations identified in the NQTL checklist; utilization review (including PA) may be applied as part of those processes.

    Note

    NQTL rationale — PA due to cost/indication

    Prior authorization is applied as a utilization management non-quantitative treatment limitation (NQTL) primarily because the drug's indication and cost were considered; no specific step-therapy sequence is specified in this document.

    Initial Therapy

    Initial Therapy

    Initial authorization is provided when indication-specific clinical criteria are met (see respective criteria sets).

    Initial therapy nodes: Refer to Initial Approval Criteria for CPP and Gender Dysphoria sections for required elements (age limits, diagnostic confirmation, specialist confirmations, tumor exclusion where applicable).

    Continuation Therapy

    Continuation Therapy

    Renewal/continuation requires ongoing clinical benefit and absence of unacceptable toxicity.

    Continuation nodes: See Renewal Criteria: continued meeting of initial criteria, absence of unacceptable toxicity, and evidence of disease response (CPP) or beneficial clinical response (gender dysphoria).

    Step Therapy

    StepRequirement / NotesCoverage Label
    1No specific step therapy sequencing is defined in this policy document. Instead, utilization management is applied via prior authorization as a non‑quantitative treatment limitation (NQTL), primarily driven by drug cost considerations as described in Appendix A.
    Prior authorization may be required to determine medical necessity and appropriate specialist documentation; the policy applies utilization review comparably to MH/SUD and M/S drugs.
    Providers should submit required clinical documentation (age, pubertal staging, diagnostic testing, specialist confirmation, and tumor exclusion when applicable) with PA requests per the policy's documentation requirements.

    Quantity Limits and Dosing

    Triptodur (triptorelin) 22.5 mg — Quantity & Dosing
    Quantity limit6 billable units (equivalent to 22.5 mg total) per 168 days
    Usual administration22.5 mg given as a single intramuscular injection once every 24 weeks (administered by a healthcare provider)
    Billing noteBilled using HCPCS J3316 where 1 unit = 3.75 mg; 6 units represent the 22.5 mg kit

    Site of Care

    Note

    Office administration and dosing interval

    Administered by a healthcare provider as a single intramuscular injection once every 24 weeks (22.5 mg per dose).

    Billing Rule

    Medicare site-of-care billing considerations

    Medicare Part B rules and any applicable Local Coverage Determinations/Articles may affect site-of-care billing and coverage for outpatient (Part B) drugs; consult CMS guidance and local contractor policies.

    Background

    Triptodur (triptorelin) is a six-month extended-release gonadotropin-releasing hormone (GnRH) agonist formulated for intramuscular administration to suppress pubertal progression. It is indicated in this policy for treatment of central precocious puberty (CPP) and for pubertal suppression in adolescents with gender dysphoria, with clinical assessment and diagnostic confirmation required prior to initiation.

    Definitions

    Qualified mental health professional (MHP) — Definition
    Minimum qualificationLicensed by statutory body with a minimum of a master’s degree or equivalent training in a relevant clinical field
    Clinical competenciesAble to identify coexisting mental health or psychosocial concerns and distinguish these from gender dysphoria or diversity
    Diagnostic competenceCompetent in using ICD (where required) or other diagnostic taxonomies to make diagnoses
    Consent & assessmentAble to assess capacity to consent and experienced/qualified to assess clinical aspects of gender dysphoria
    Ongoing educationUndergo continuing education related to gender dysphoria, incongruence, and diversity
    DSM-5-TR Gender Dysphoria criteria — Summary

    Medicare Local Coverage and Contractors

    Documentation Required

    Medicare coverage documentation

    Medicare Part B coverage rules may apply; compliance with applicable NCDs, LCDs, and LCAs is required and CMS coverage documents can be searched at the CMS coverage database link provided.

    • https://www.cms.gov/medicare-coverage-database/search.aspx

    Medicare Part B coverage rules and Local/National Coverage Determinations may apply to outpatient drugs. Appendix 2 directs users to the CMS coverage database (https://www.cms.gov/medicare-coverage-database/search.aspx) and lists Medicare Administrative Contractor (MAC) jurisdictions and contractors by jurisdiction identifiers and covered states. Examples include National Government Services, Inc., Noridian Healthcare Solutions, LLC, Wisconsin Physicians Service Insurance Corp (WPS), Novitas Solutions, Inc., First Coast Service Options, Inc., Palmetto GBA, and CGS Administrators, LLC, among others; providers should consult the CMS database and the listed MACs for jurisdiction-specific billing and coverage guidance.

    Policy Summary
    PayerViva Health
    PolicyTriptodur® (triptorelin) (Intramuscular) — Coverage Criteria
    Policy CodePolicy IC-0308
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial PA valid for 12 months and renewable every 12 months) and include required clinical documentation to support the indication.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and Prior AuthorizationInitial TherapyContinuation TherapyStep TherapyQuantity Limits and DosingSite of CareBackgroundDefinitionsMedicare Local Coverage and Contractors
    Note

    No action specified

    No additional provider-action item text is specified in the source document for this placeholder.

    Documentation Required

    Submit required clinical documentation with PA

    For initial authorization include documentation of the member's age and clinical findings (e.g., onset of secondary sexual characteristics, pubertal LH response to GnRH stimulation, advanced bone age), confirmation of diagnosis by the appropriate specialists (qualified MHP for gender dysphoria; pediatric endocrinologist for CPP/adolescents), and diagnostic testing to rule out tumors (brain imaging, pelvic/testicular/adrenal ultrasound, and hCG levels).

    • Age and pubertal staging (e.g., Tanner stage, onset of secondary sexual characteristics)
    • Pubertal LH response to GnRH stimulation and sex steroid levels
    • Bone age assessment (advanced >2 SD for CPP)
    • Tumor exclusion testing: brain imaging, pelvic/testicular/adrenal ultrasound, hCG levels
    • Specialist confirmation: pediatric endocrinologist for CPP/adolescents; qualified MHP for gender dysphoria
    Documentation Required

    Follow Medicare Part B coverage determinations when applicable

    Medicare Part B coverage rules may apply; comply with CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) where applicable and use the CMS coverage database link provided for reference.

    • Search NCD/LCD/LCA documents at https://www.cms.gov/medicare-coverage-database/search.aspx
    • Follow applicable Medicare coverage and billing guidance for outpatient (Part B) drugs
    Denial Risk

    Monitor for toxicity — may cause renewal denial

    Renewal may be denied if the member experiences unacceptable toxicity from the drug; examples include psychiatric events, convulsions, severe cutaneous adverse reactions (e.g., SJS/TEN, DRESS, AGEP), or signs/symptoms of pseudotumor cerebri/idiopathic intracranial hypertension.

    • Psychiatric events (emotional lability, irritability, anger, aggression)
    • Convulsions
    • Severe cutaneous adverse reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis, DRESS, AGEP)
    • Signs/symptoms of pseudotumor cerebri / idiopathic intracranial hypertension (headache, papilledema, blurred vision, diplopia, vision loss, eye pain, tinnitus, dizziness, nausea)
    Prior Authorization

    Expect utilization management per NQTLs

    Prior authorization may be applied because the NQTL checklist identified the drug's indication and cost as considerations; utilization management (including PA) is applied comparably to MH/SUD and medical/surgical drugs.

    Duration criterionMarked incongruence between experienced/expressed gender and natal gender for at least 6 months
    ManifestationsAt least two of: incongruence with primary/secondary sex characteristics, desire to be rid of or prevent development of sex characteristics, desire for characteristics of other gender, desire to be the other gender, desire to be treated as the other gender, conviction of typical feelings/reactions of other gender
    Associated impairmentCondition must be associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning
    E30.1 — Precocious puberty (ICD-10)
    ICD-10 codeE30.1
    DescriptionPrecocious puberty
    UsageListed as a covered diagnosis for Triptodur therapy in Appendix 1
    F64.x series — Gender identity ICD-10 codes
    Code seriesF64.x series
    Included codesF64.0, F64.1, F64.2, F64.8, F64.9 (discontinued effective 10/1/26), F64.A (in remission, effective 10/1/26)
    ContextListed in Appendix 1 as gender identity / trans-related ICD-10 diagnosis codes covered by this policy